Foyston Gordon & Payne Inc Lowers Stock Holdings in Henry Schein, Inc. $HSIC

Foyston Gordon & Payne Inc lessened its position in Henry Schein, Inc. (NASDAQ:HSIC) by 39.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,136 shares of the company’s stock after selling 44,691 shares during the quarter. Foyston Gordon & Payne Inc owned approximately 0.06% of Henry Schein worth $4,589,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HSIC. CYBER HORNET ETFs LLC acquired a new position in Henry Schein in the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the second quarter worth about $27,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Henry Schein in the second quarter valued at approximately $43,000. Sentry Investment Management LLC grew its holdings in shares of Henry Schein by 132.1% in the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after purchasing an additional 515 shares in the last quarter. Finally, Evelyn Partners Investment Management Services Ltd acquired a new position in shares of Henry Schein in the second quarter valued at approximately $62,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling at Henry Schein

In related news, CEO Stanley M. Bergman sold 10,785 shares of Henry Schein stock in a transaction on Friday, February 27th. The shares were sold at an average price of $81.20, for a total transaction of $875,742.00. Following the sale, the chief executive officer directly owned 309,092 shares in the company, valued at $25,098,270.40. This trade represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.08% of the company’s stock.

Henry Schein Trading Up 1.1%

NASDAQ:HSIC opened at $82.39 on Friday. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29. The stock has a market cap of $9.45 billion, a P/E ratio of 25.20, a P/E/G ratio of 2.44 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38. The stock has a 50-day simple moving average of $77.85 and a 200-day simple moving average of $72.18.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on HSIC shares. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday. Robert W. Baird set a $100.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research report on Monday, February 23rd. Evercore lifted their target price on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Leerink Partners upped their price target on Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a report on Tuesday, February 24th. Finally, UBS Group increased their price target on Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $85.58.

Key Stories Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.